|
|
 |
| |
|
Home > Fortune 500 Companies > Amgen Inc
Amgen Inc
Amgen Inc is a fortune 500 stock listed company trading under the symbol AMGN.
The company has a good proven stock performance record.
Amgen is a leading human therapeutics company in the biotechnology industry. The company was incorporated 1980 and is based in Thousand Oaks, California. Amgen, Inc., It is a biotechnology company that engages in the discovery, development, manufacture, and marketing of human therapeutics based on advances in cellular and molecular biology. It offers human therapeutic products in the areas of inflammation, nephrology, and supportive cancer care. The company’s principal products include Aranesp and EPOGEN, which stimulate the production of red blood cells to treat anemia; Neulasta and NEUPOGEN that stimulate the production of neutrophils, a white blood cell that enables the body fight infections and Enbrel, which blocks the biologic activity of tumor necrosis factor (TNF) by inhibiting TNF, a substance induced in response to inflammatory and immunological responses, such as rheumatoid arthritis and psoriasis. The company offers its products to healthcare providers, including clinics, dialysis centers, hospitals, and pharmacies primarily in the United States, Europe ETC. It has a joint venture with Kirin Brewery Company, Limited, as well as a co-promotion agreement with Wyeth. Amgen’s close partnership with medical professionals is a crucial part of the company’s commitment to patients.
Amgen Ventures funds early-stage companies developing human therapeutics. While the fund’s focus is primarily in areas of current therapeutic interest to Amgen, they also seek out novel modalities with the potential to address targets in both current and emerging therapeutic areas of interest. The fund also considers important technology breakthroughs that may provide the opportunity to advance the creation of human therapeutics. Investments are made on a case-by-case basis, but Amgen Ventures typically invests up to 1 to 3 million dollars per company per round. Amgen Ventures ownership is most often less than 15 percent. Amgen does not pay a dividend on stock, and does not foresee doing so in the immediate future. Accordingly, Amgen does not offer a DRIP (Dividend Reinvestment Program). Amgen Inc.'s Corporate Governance Quotient as of the 1st of April 2006 is better than 17.7 percent of S&P 500 companies and 83.1 percent of Pharmaceuticals & Biotechnology companies.
R&D Vision focuses their efforts on developing therapies that have a beneficial effect on patients suffering from the greatest unmet medical needs.
The Company seeks to achieve superior customer satisfaction through innovative products, comprehensive health and related benefits choices, effective service and easy-to-understand information.
Back to Fortune 500 Companies
|
|
|
|
|
|
|